Hadasit Bio-Holdings

Press Releases

Investment in Cell Cure Neurosciences Ltd.

Feb. 9, 2016

HBL - Hadasit Bio-Holdings Ltd.

(the “Company”)

 

                                                                                                                                                9 February 2016

Attn:                                                                      Attn:

Israel Securities Authority                            Tel Aviv Stock Exchange Ltd.

www.isa.gov.il                                                   www.tase.co.il

 

 

Re: Investment in Cell Cure Neurosciences Ltd.

 

Further to the disclosure made by the Company included in Section 2.2.2.2 of the quarterly report of the Board of Directors of the Company for the third quarter of 2015, as published by the Company on 25 November 2015, and its amendment of 26 November 2015 (MAGNA reference no: 2015-01-164493 and 2015-01-166134, respectively), regarding the resolution of the Board of Directors of Cell Cure Neurosciences Ltd. (“Cell Cure”) for an additional capital raising of up to USD 5,000,000 by way of a convertible loan from the existing shareholders of Cell Cure on a “Capital Call” basis based on Cell Cure’s needs (the “Convertible Loan”), the Company hereby announces that it has informed Cell Cure of its participation totaling a sum of USD 381,000, an amount reflecting 13.14% of the Company’s pro-rata portion in the Convertible Loan to date.

 

True to date, the Company holds 21.2% of Cell Cure’s issued share capital (on a non-diluted basis). Assuming the conversion of all of Cell Cure’s convertible loans, the Company will hold 18.63% of the issued share capital of Cell Cure (on a non-diluted basis).[1]

 

 

Respectfully,

 

HBL - Hadasit Bio-Holdings Ltd.

By: Ms. Tamar Kfir CEO



[1] The Company’s percentage holdings in Cell Cure on the presumption of the conversion of all convertible loans (not including an annual interest rate of 3%) by Cell Cure, is true to date of this immediate report.HBL - Hadasit Bio-Holdings Ltd.

(the “Company”)

 

                                                                                                                                                9 February 2016

Attn:                                                                      Attn:

Israel Securities Authority                            Tel Aviv Stock Exchange Ltd.

www.isa.gov.il                                                   www.tase.co.il

 

 

Re: Investment in Cell Cure Neurosciences Ltd.

 

Further to the disclosure made by the Company included in Section 2.2.2.2 of the quarterly report of the Board of Directors of the Company for the third quarter of 2015, as published by the Company on 25 November 2015, and its amendment of 26 November 2015 (MAGNA reference no: 2015-01-164493 and 2015-01-166134, respectively), regarding the resolution of the Board of Directors of Cell Cure Neurosciences Ltd. (“Cell Cure”) for an additional capital raising of up to USD 5,000,000 by way of a convertible loan from the existing shareholders of Cell Cure on a “Capital Call” basis based on Cell Cure’s needs (the “Convertible Loan”), the Company hereby announces that it has informed Cell Cure of its participation totaling a sum of USD 381,000, an amount reflecting 13.14% of the Company’s pro-rata portion in the Convertible Loan to date.

 

True to date, the Company holds 21.2% of Cell Cure’s issued share capital (on a non-diluted basis). Assuming the conversion of all of Cell Cure’s convertible loans, the Company will hold 18.63% of the issued share capital of Cell Cure (on a non-diluted basis).[1]

 

 

Respectfully,

 

HBL - Hadasit Bio-Holdings Ltd.

By: Ms. Tamar Kfir CEO


[1] The Company’s percentage holdings in Cell Cure on the presumption of the conversion of all convertible loans (not including an annual interest rate of 3%) by Cell Cure, is true to date of this immediate report.

 
 

Press Releases Archive